Intracameral Vigamox® (Moxifloxacin 0.5%) i Non-Toxic and Effective in Preventing Endophthalmiti in a Rabbit Model

Purpoe To determine whether Vigamox® (moxifloxacin 0.5% ophthalmic olution) can be afely injected intracamerally to prevent taphylococcu aureu endophthalmiti in a rabbit model. Deign Animal tudy. Method The afety and bactericidal-effectivene of Vigamox® were evaluated in three tage uing 189 New Zealand White rabbit. (tage 1) The toxicity of two intravitreal doe of Vigamox® (moxifloxacin 500, 250 μg) wa compared with vancomycin (1 mg) and aline. (tage 2) A reproducible rabbit model of taphylococcu aureu endophthalmiti wa etablihed. (tage 3) The bactericidal effect of intracameral Vigamox® (moxifloxacin 500, 250, 125, 50 μg) wa compared with vancomycin (1 mg) and aline. Intracameral antibiotic therapy commenced immediately after taphylococcu aureu intravitreal challenge (5000 cfu). Toxicity wa evaluated by maked clinical examination uing a lit-lamp, an indirect ophthalmocope, and corneal-ultraound pachymetry. The clinical examination included the exterior eye, cornea, anterior chamber, vitreou, and retina. The preentation were graded on a everity cale of 0, 0.5, 1, 2, and 3. The bactericidal efficacy wa determined uing intracameral colony count. Reult In the toxicity tudie without bacterial challenge, the clinical core of rabbit injected intracamerally with Vigamox® were tatitically equivalent to rabbit given intracameral vancomycin or aline. In the efficacy tudie, eye treated intravitreally with Vigamox®, at all doe, or vancomycin were negative for taphylococcu aureu and nontreated control remained culture-poitive. Concluion Vigamox® appear to be nontoxic for intracameral injection and effective in preventing experimental endophthalmiti in the rabbit model. Further tudie will determine the clinical role of intracameral Vigamox® for urgical prophylaxi and potoperative therapy.